Business, energy, technology, markets and global industry news from Business News Today

Firelink

PharmaDeviceNews Firelink
Johnson & Johnson’s $1 billion Firefly Bio acquisition adds the preclinical Firelink degrader antibody conjugate platform to its oncology pipeline, strengthening its research into KRAS-driven cancers and other difficult-to-treat solid tumors. Representative image.
Pharma & Biotech

Johnson & Johnson just spent $1bn on a preclinical cancer platform: What must Firefly Bio prove next?

Johnson & Johnson closes its $1 billion Firefly Bio deal, adding a preclinical degrader antibody conjugate platform for KRAS-driven cancers.

Read More
Representative image of oncology researchers reviewing molecular data in a biotechnology lab, reflecting Johnson & Johnson’s Firefly Bio deal and the race to advance degrader antibody conjugates for hard-to-treat solid tumors.
Pharma & Biotech

Why Johnson & Johnson is paying $1bn for Firefly Bio’s cancer drug platform

Johnson & Johnson is chasing the next cancer drug platform. Firefly Bio adds promise, but clinical proof remains the real test.

Read More